

SOHM India Obtains Manufacturing License for Generic Pharmaceuticals Increasing Profit Margins and Scalability of Operations



SOHM India Obtains Manufacturing License for Generic Pharmaceuticals Increasing Profit Margins and Scalability of Operations

Licensed Centralized Manufacturing Facility to Produce SOHM's Generic Pharmaceutical Products an Important Operational Milestone

BUENA PARK, CA Feb 24, 2009 – SOHM, Inc. (Other OTC:SHMN.PK – News), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, today announced that the Company has obtained a direct manufacturing license for generic pharmaceuticals. The classification and industry position allows for a significant increase in profit margins and scalability of manufacturing operations. This license completes SOHM's infrastructure development for the corporate manufacturing hub located in India. Global sales contracts, production and export of generic pharmaceutical preparations such as tablets, capsules, ointments, and liquids are fully operational.

Vice President for Corporate Strategy at SOHM, Inc., Shailesh Shah, stated, "Our successful establishment of a licensed centralized manufacturing facility to produce SOHM's generic pharmaceutical products is an important operational milestone. This authorization provides the Company with a manufacturing capability that can be used for all of our products. Growth in generic pharmaceutical sales is expected to be strong in Africa, Latin America, and Southeast Asia and we are preparing now to take market share in these untapped and growing markets. Emerging markets are key to the pharmaceutical industry's future growth with more than 85 percent of world consumers remaining underserved or with limited access to medicines."

About SOHM, Inc.

SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia.
www.sohm.com

Safe Harbor Statement

This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based.

Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results. For more information, please contact:

SOHM, Inc.

Investor Relations

(714) 522-6700